Electrocardiographic criteria for left ventricular hypertrophy and cardiovascular risk in hypertensives. VIIDA study;Criterios electrocardiográficos de hipertrofia ventricular izquierda y perfil de riesgo cardiovascular en hipertensos. Estudio VIIDA

Revista Espanola de Cardiologia

Volumn 60, Issue 2, 2007, Pages 148-156

  González Juanatey, José Ramon ^a   Cea Calvo, Luis ^b   Bertomeu, Vicente ^c   Aznar, Joaquín ^d  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b Medical affairs Merck sharp and Dohme ltd   (Spain)

^c HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^d Hospital Provincial Nuestra Señora de Gracia   (Spain)

Author keywords

Arterial hypertension; Cardiovascular disease; Electrocardiography; Hypertrophy

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PATIENT IDENTIFICATION; PREVALENCE; RISK ASSESSMENT; SCORING SYSTEM; SEX DIFFERENCE; ANALYSIS OF VARIANCE; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; HOSPITALIZATION; METHODOLOGY; MULTICENTER STUDY; PATHOPHYSIOLOGY; PERIPHERAL VASCULAR DISEASE; RISK; SEX RATIO; SPAIN; STANDARD;

ANALYSIS OF VARIANCE; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MYOCARDIAL INFARCTION; ODDS RATIO; PERIPHERAL VASCULAR DISEASES; PREVALENCE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SEX FACTORS; SPAIN;

EID: 33947595256     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13099461     Document Type: Article

References (25)

1. Verdecchia P, Angeli F, Reboldi G, Carluccio E, Benemio G, Gattobigio R, et al. Improved cardiovascular risk stratification by a simple ECG index in hypertension. Am J Hypertens. 2003;16:646-52.
2. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-6.
3. Schillaci G, Verdecchia P, Porcellati C, Cuccurullo O, Cosco C, Perticone F. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension. 2000;35:580-6.
4. Boden WE, Kleiger RE, Schechtman KB, Capone RJ, Schwartz DJ, Gibson RS. Clinical significance and prognostic importance of left ventricular hypertrophy in non-Q-wave acute myocardial infarction. Am J Cardiol. 1988;62:1000-4.
5. Ghali JK, Liao Y, Simmons B, Castaner A, Cao G, Cooper RS. The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med. 1992;117:831-6.
6. Parfrey PS, Harnett JD, Griffiths SM, Taylor R, Hand J, King A, et al. The clinical course of left ventricular hypertrophy in dialysis patients. Nephron. 1990;55:114-20.
7. Verdecchia P, Porcellati C, Reboldi G, Gattobigio R, Borgioni C, Pearson TA, et al. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation. 2001; 104:2039-44.
8. Verdecchia P, Reboldi G, Gattobigio R, Bentivoglio M, Borgioni C, Angeli F, et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension. 2003;41:218-23.
9. 3 European Society of Hypertension-European Society of Cardiology guidelines for management of arterial hypertension. J Hypertens. 2003;21:1011-53.
10. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 report. JAMA. 2003;289:2560-72.
11. González-Juanatey JR, Mazon Ramos P, Soria Arcos F, Barrios Alonso V, Rodríguez Padial L, et al. Actualización (2003) de las guías de práctica clínica de la Sociedad Española de Cardiología en hipertensión. Rev Esp Cardiol. 2003;56:487-97.
12. Sokolow M, Lyon T. Ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J. 1949;37:161-86.
13. Casale PN, Devereux RB, Alonso DR, Campo E, Kligfield P. Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: validation with autopsy findings. Circulation. 1987;75:565-72.
14. Rodríguez L. Usefulness of total-lead QRS voltage for determining the presence of left ventricular hypertrophy in systemic hypertension. Am J Cardiol. 1991;68:261-2.
15. Schillaci G, Verdecchia P, Borgioni C, Ciucci A, Guerrieri M, Zampi I et al. Improved electrocardiographic diagnosis of left ventricular hypertrophy. J Am J Cardiol. 1994;74:714-9.
16. Molloy TJ, Okin PM, Devereux RB, Kligfield P. Electrocardiographic detection of left ventricular hypertrophy by the simple QRS voltage-duration product. J Am Coll Cardiol. 1992;20:1180-6.
17. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Dahlof B for the LIFE Study Investigators. Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators. Hypertension. 2000;36:766-73.
18. De Simone G, Devereux RB, Roman MJ, Alderman MH, Laragh JH. Relation of obesity and gender to left ventricular hypertrophy in normotensive and hypertensive adults. Hypertension. 1994;23: 600-6.
19. Bella JN, Devereux RB, Roman MJ, O'Grady MJ, Welty TK, Lee ET, et al. for the Strong Heart Study Investigators. Relations of left ventricular mass to fat-free and adipose body mass: the strong heart study. Circulation. 1998;98:2538-44.
20. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation. 1994;90:1786-93.
21. Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation. 2001;104: 1615-21.
22. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 2004;292:2343-9.
23. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, De Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359: 995-1003.
24. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation. 2003;108:684-90.
25. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45:712-9.